药明合联：2024年报点评：增长强劲，看好一站式偶联药物CRDMO龙头长期发展-20250328
[Table_Info] 维持优于大市 Maintain OUTPERFORM 研究报告 Research Report 27 Mar 2025 药明合联 WuXi XDC Cayman (2268 HK) 2024 年报点评：增长强劲，看好一站式偶联药物 CRDMO 龙头长期发展 24FY Review: Robust Growth with Long-term Development of Leading One-Stop CRDMO for XDC [Table_yemei1] 观点聚焦 Investment Focus | 评级 | 优于大市 OUTPERFORM | | --- | --- | | 现价 | HK$41.90 | | 目标价 | HK$49.10 | | HTI ESG | 3.3-3.5-4.5 | | E-S-G: 0-5, (Please refer to the Appendix for ESG comments) | | | 市值 | HK6.47bn | | 日交易额 (3 个月均值) | US$24.53mn | | 发行股票数目 | 1,2 ...